- Regulatory Status
- RUO
- Other Names
- Killer cell lectin like receptor K1, KLRK1, KLR, CD314, NKG2-D, NKG2-D-Activating NK Receptor, NKG2-D Type II Integral Membrane Protein, D12S2489E
Cat # | Size | Price | Quantity Check Availability | ||
---|---|---|---|---|---|
781902 | 10 µg | $94.00 | |||
781904 | 25 µg | $171.00 | |||
781906 | 100 µg | $370.00 | |||
781908 | 500 µg | $1465.00 |
Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
Natural killer group 2, member D (NKG2D) is a type II transmembrane protein, a C-type lectin-like receptor that is expressed as a homodimer. NKG2D has a short intracellular domain that possesses charged amino acids that interact with the adaptor proteins DAP10 and/or DAP12 involved in signal transduction. In mice, NKG2D is expressed as two isoforms (long and short) that interact with the adaptor proteins differentially. NKG2D-short interacts with DAP10 and DAP12, and the long isoform interacts only with DAP10. In humans, NK cells express only the NKG2D-long isoform, and therefore DAP10 takes part in the signal transduction. Activation of NKG2D induces secretion of cytokines and chemokines, cytotoxic activity, and proliferation of effector cells. The expression of CEACAM1 on activated NK cells acts as an inhibitory receptor for the NKG2D-mediated cytolysis. The expression of activating receptors NKG2D, NKp30, NKp46, and DNAM-1 is downregulated in peripheral NK cells of patients with gastric cancer. Plasma levels of TGF-β1 are elevated in gastric patients, and it has been described that TGF-β1 can induce the downregulation of NK activating receptors in vitro. Decreased expression of activating receptors in NK cells is associated with gastric cancer progression.
Product Details
- Source
- Human NKG2D, amino acid Phe78 - Val216 (Accession # P26718) was expressed in CHO cells. The amino terminus contains Met- 6His + GCN4 (LZ) + linker region.
- Molecular Mass
- The 189 amino acid recombinant protein has a predicted molecular mass of approximately 21.6 kD. The DTT-reduced and non-reduced proteins migrate at approximately 27 – 35 kD by SDS-PAGE. The predicted N-terminal amino acid is Met.
- Purity
- >95%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 µm filtered protein solution is in PBS pH 7.2.
- Endotoxin Level
- Less than 0.1 EU per µg protein as determined by the LAL method.
- Concentration
- 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Immobilized recombinant human NKG2D binds to recombinant human MICB in a dose-dependent manner using a functional ELISA. The ED50 for this effect is 15 – 60 ng/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Homodimer
- Distribution
-
NK cells, CD8 αβ, T cells, and γδ T cells, invariant NKT (iNKT), innate lymphoid cells (ILCs), and CD4+ T cells under some pathological conditions.
- Function
- NKG2D takes part in the innate immune response. It is induced by IL-15 in intraepithelial lymphocytes and downregulated by virus infection (SV40).
- Interaction
- Gastrointestinal epithelium, stressed airway epithelial cells, fibroblasts, cancer cell lines, cervical cancer, and myelomonocytic leukemia.
- Ligand/Receptor
- MICA, MICB, ULBP ligands (1 to 6), and human cytomegalovirus glycoprotein, UL16.
- Bioactivity
- Recombinant human NKG2D binds recombinant MICB in a dose-dependent manner using a functional ELISA.
- Cell Type
- NK cells, NKT cells, T cells
- Biology Area
- Immunology, Costimulatory Molecules
- Molecular Family
- CD Molecules, Soluble Receptors
- Antigen References
-
- Houchins JP, et al. 1991. J Exp Med. 173:1017.
- Diefenbach A, et al. 2000. Nat Immunol. 1:119.
- Roberts AI, et al., 2001. J Immunol. 167:5527.
- Hosomi S, et al. 2013. Eur J Immunol. 43:2473.
- Klose CSN, et al. 2014. Cell. 157:340.
- Tong HV, et al. 2015. BMC Infect Dis. 15:25.
- Han B, et al. 2018. J Immunol Res. 2018:6248590.
- Stojanovic A, et al. 2018. Frot Immunol. 9:827.
- Gene ID
- 22914 View all products for this Gene ID
- UniProt
- View information about NKG2D on UniProt.org